These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19280919)

  • 1. [B lymphocyte abnormalities in connective tissue disorders].
    Sato S
    Nihon Rinsho; 2009 Mar; 67(3):477-81. PubMed ID: 19280919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [B-cell-targeted therapy in the treatment of autoimmune diseases].
    Roll P; Tony HP
    Z Rheumatol; 2009 May; 68(3):255-9. PubMed ID: 19384549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
    Faurschou M; Jayne DR
    Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
    Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
    J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P; Jamin C; Saraux A
    Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of B cell-targeted therapies in Sjögren's syndrome.
    Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
    Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
    Valor L; López-Longo FJ
    Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New biological therapy in systemic lupus erythematosus].
    Morita K; Fujio K
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():539-44. PubMed ID: 23513898
    [No Abstract]   [Full Text] [Related]  

  • 14. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
    Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
    Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.
    Zambruno G; Borradori L
    J Invest Dermatol; 2008 Dec; 128(12):2745-7. PubMed ID: 18997839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
    Baert L; Manfroi B; Casez O; Sturm N; Huard B
    J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 18. CD20-targeted therapy: the next generation of antibodies.
    van Meerten T; Hagenbeek A
    Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell targeted therapeutics in clinical development.
    Blüml S; McKeever K; Ettinger R; Smolen J; Herbst R
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S4. PubMed ID: 23566679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.